Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peanut Immunotherapy Dissolving Film PK Study
NCT03070561Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2014
- Primary completion
- May 2015
- Modality
- Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by Johns Hopkins University. Primary endpoints: Elimination half life of Ara H2 in sublingual placement at 3 days, Elimination half life of Ara H2 in buccal placement at 3 days and 1 more. Started Jan 2014; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03070561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070561.